3
6
1
↑3
↓6
—1
Evidence suggests Semaglutide maydecreaseEfficacy.
6 studies (10 claims)
Moderate consensus
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| semaglutide | No effect - forgive nonadherence, meaning that strong weight loss efficacy persists despite missed doses | weight loss efficacy | Human | simulated patients | — | Incretin mimetics for weight loss forgive nonadherence. |
| semaglutide prescription | Decreases - adjusted odds ratios were | prescription of high-efficacy glucose-lowering medications | Human | AI/AN patients with uncomplicated T2D | — | Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis. |
| semaglutide prescription | Decreases - adjusted odds ratios were | prescription of high-efficacy glucose-lowering medications | Human | Asian patients with uncomplicated T2D | — | Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis. |
| semaglutide prescription | Decreases - adjusted odds ratios were | prescription of high-efficacy glucose-lowering medications | Human | Black patients with uncomplicated T2D | — | Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis. |
| semaglutide prescription | Decreases - adjusted odds ratios were | prescription of high-efficacy glucose-lowering medications | Human | Hispanic patients with uncomplicated T2D | — | Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis. |
| semaglutide prescription | Decreases - adjusted odds ratios were | prescription of high-efficacy glucose-lowering medications | Human | NH/PI patients with uncomplicated T2D | — | Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis. |
| combination of semaglutide with the amylin analogue cagrilintide (CagriSema) | Increases - have shown | strong efficacy | Human | — | — | Recent advances in peptide-based therapies for obesity and type 2 diabetes. |